Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques-Eric Gottenberg

Showing results (141-150 of 311) with videos related to

Pageof 32
Sort By:
Scientific Reports|January 21, 2016
Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR CohortRaphaèle Seror, Saida Boudaoud, Stephan Pavy, et al.
Free Radical Biology & Medicine|July 7, 2015
High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosisKhalil Bourji, Alain Meyer, Emmanuel Chatelus, et al.
Clinical Rheumatology|December 15, 2016
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)Florenzo Iannone, Delphine S Courvoisier, Jacques Eric Gottenberg, et al.
Arthritis Research & Therapy|February 26, 2020
Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndromePierre-Marie Duret, Nicolas Meyer, Alain Saraux, et al.
Annals of the Rheumatic Diseases|November 10, 2020
Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trialAlan N Baer, Jacques-Eric Gottenberg, E William St Clair, et al.
BMJ Open|June 17, 2025
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trialTristan Pascart, Bruno Fautrel, Jacques-Eric Gottenberg, et al.
Clinical and Experimental Rheumatology|December 17, 2021
Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FiRST questionnaire and physician's opinionJean-Jacques Dubost, Marion Couderc, Bruno Pereira, et al.
Arthritis and Rheumatism|December 1, 2007
Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathyBenjamin Terrier, Catherine Lacroix, Loïc Guillevin, et al.
Rheumatology and Therapy|October 29, 2021
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial DataMarkus Rehberg, Clemens Giegerich, Amy Praestgaard, et al.
Rheumatology (Oxford, England)|January 30, 2016
Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registryClément Lahaye, Martin Soubrier, Aurélien Mulliez, et al.
Pageof 32

Showing results (141-150 of 311) with videos related to

Sort By:
Pageof 32
Scientific Reports|January 21, 2016
Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR CohortRaphaèle Seror, Saida Boudaoud, Stephan Pavy, et al.
Free Radical Biology & Medicine|July 7, 2015
High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosisKhalil Bourji, Alain Meyer, Emmanuel Chatelus, et al.
Clinical Rheumatology|December 15, 2016
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)Florenzo Iannone, Delphine S Courvoisier, Jacques Eric Gottenberg, et al.
Arthritis Research & Therapy|February 26, 2020
Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndromePierre-Marie Duret, Nicolas Meyer, Alain Saraux, et al.
Annals of the Rheumatic Diseases|November 10, 2020
Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trialAlan N Baer, Jacques-Eric Gottenberg, E William St Clair, et al.
BMJ Open|June 17, 2025
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trialTristan Pascart, Bruno Fautrel, Jacques-Eric Gottenberg, et al.
Clinical and Experimental Rheumatology|December 17, 2021
Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FiRST questionnaire and physician's opinionJean-Jacques Dubost, Marion Couderc, Bruno Pereira, et al.
Arthritis and Rheumatism|December 1, 2007
Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathyBenjamin Terrier, Catherine Lacroix, Loïc Guillevin, et al.
Rheumatology and Therapy|October 29, 2021
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial DataMarkus Rehberg, Clemens Giegerich, Amy Praestgaard, et al.
Rheumatology (Oxford, England)|January 30, 2016
Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registryClément Lahaye, Martin Soubrier, Aurélien Mulliez, et al.
Pageof 32